Evidence map›Paper›PMID 34399998›Full record

Trial reportEuropean urology2021

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.

Patrick Cheung, Samir Patel, Scott A North, Arjun Sahgal, William Chu, Hany Soliman, Belal Ahmad, Eric Winquist, Tamim Niazi, Francois Patenaude and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06489821 (STereotactic Body Radiotherapy), which is not on this map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06489821 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

STereotactic Body Radiotherapy (SBRT) After oligoprogRession Metastatic Breast Cancer (STAR-B)

TypeinterventionalSponsorJuravinski Cancer CenterRan2024 to 2027Enrolled36ConditionsMetastatic Breast Cancer, OligoprogressionArmsStereotactic body radiotherapy
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications.International journal of urology : official journal of the Japanese Urological Association · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 1 country.

Patrick CheungDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Samir PatelDivision of Radiation Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Scott A NorthDivision of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Arjun SahgalDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
William ChuDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Hany SolimanDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Belal AhmadDivision of Radiation Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, ON, Canada.
Eric WinquistDivision of Medical Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, ON, Canada.
Tamim NiaziDivision of Radiation Oncology, Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Francois PatenaudeDepartment of Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Gerald LimDivision of Radiation Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Daniel Yick Chin HengDivision of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Arbind DubeyDepartment of Radiation Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
Piotr CzaykowskiDepartment of Medical Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
Rebecca K S WongRadiation Medicine Program, Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Anand SwaminathDepartment of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Scott C MorganDivision of Radiation Oncology, Department of Radiology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada.
Rupi MangatOzmosis Research Inc., Toronto, ON, Canada.
Sareh KeshavarziDepartment of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Georg A BjarnasonDivision of Medical Oncology, Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address: georg.bjarnason@sunnybrook.ca.
Sunnybrook Health Science Centre · CACancerCare Manitoba · CAJewish General Hospital · CAUniversity of Alberta · CAUniversity of Calgary · CAUniversity of Toronto · CAWestern University · CAJuravinski Cancer Centre · CAOzmosis Research (Canada) · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy.

objectiveTo determine the local control (LC), progression-free survival (PFS), cumulative incidence of changing systemic therapy, and overall survival (OS) after SRT to oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients who are on tyrosine kinase inhibitor (TKI) therapy. DESIGN, SETTING, AND

participantsA prospective multicenter study was performed to evaluate the use of SRT in oligoprogressive mRCC patients. Patients with mRCC who had previous stability or response after ≥3 mo of TKI therapy were eligible if they developed progression of five of fewer metastases. Thirty-seven patients with 57 oligoprogressive tumors were enrolled.

interventionOligoprogressive tumors were treated with SRT, and the same TKI therapy was continued afterward. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Competing risk analyses and the Kaplan-Meir methodology were used to report the outcomes of interest. RESULTS AND LIMITATIONS: The median duration of TKI therapy prior to study entry was 18.6 mo; 1-yr LC of the irradiated tumors was 93% (95% confidence interval [CI] 71-98%). The median PFS after SRT was 9.3 mo (95% CI 7.5-15.7 mo). The cumulative incidence of changing systemic therapy was 47% (95% CI 32-68%) at 1 yr, with a median time to change in systemic therapy of 12.6 mo (95% CI 9.6-17.4 mo). One-year OS was 92% (95% CI 82-100%). There were no grade 3-5 SRT-related toxicities.

conclusionsLC of irradiated oligoprogressive mRCC tumors was high, and the need to change systemic therapy was delayed for a median of >1 yr. PATIENT SUMMARY: The use of stereotactic radiotherapy in metastatic kidney cancer patients, who develop growth of a few tumors while on oral targeted therapy, can significantly delay the need to change to the next line of drug therapy.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRadiosurgeryFemaleHumansMaleProspective StudiesProtein Kinase InhibitorsRetrospective StudiesProtein Kinase InhibitorsKidney cancerOligoprogressionSABRSBRTStereotactic ablative radiotherapyStereotactic body radiotherapyStereotactic radiotherapyTyrosine kinase inhibitor

Identifiers

PMID34399998
OpenAlexW3194741964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.